{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:32:48Z","timestamp":1784237568387,"version":"3.55.0"},"reference-count":40,"publisher":"Japan Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej25-0251","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T22:07:08Z","timestamp":1756937228000},"page":"1327-1337","source":"Crossref","is-referenced-by-count":2,"title":["Real-world clinical experience of reduced-dose initiation of lenvatinib in Japanese patients with radioiodine-refractory differentiated thyroid cancer"],"prefix":"10.1507","volume":"72","author":[{"given":"Yomi","family":"Nakashima","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3430-5796","authenticated-orcid":false,"given":"Ichiro","family":"Horie","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Arimori","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"},{"name":"Department of Nursing Science, Faculty of Nursing and Nutrition, University of Nagasaki, Nagasaki 851-8195, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinpei","family":"Nishikido","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Nakaji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Niri","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Sako","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Haraguchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Ikeoka","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akie","family":"Moriuchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"},{"name":"Department of Nagasaki Clinical Studies, Radiation Effects Research Foundation, Nagasaki 850-0013, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Usa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"},{"name":"Takashi Nagai Memorial International Hibakusha Medical Center, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, et al. (2006) Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91: 313\u2013319.","DOI":"10.1210\/jc.2005-1322"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2 Sherman SI (2003) Thyroid carcinoma. Lancet 361: 501\u2013511.","DOI":"10.1016\/S0140-6736(03)12488-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Sciuto R, Romano L, Rea S, Marandino F, Sperduti I, et al. (2009) Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol 20: 1728\u20131735.","DOI":"10.1093\/annonc\/mdp050"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4 Xing M, Haugen BR, Schlumberger M (2013) Progress in molecular-based management of differentiated thyroid cancer. Lancet 381: 1058\u20131069.","DOI":"10.1016\/S0140-6736(13)60109-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Pacini F, Ito Y, Luster M, Pitoia F, Robinson B, et al. (2012) Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab 7: 541\u2013554.","DOI":"10.1586\/eem.12.36"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Araque KA, Gubbi S, Klubo-Gwiezdzinska J (2020) Updates on the management of thyroid cancer. Horm Metab Res 52: 562\u2013577.","DOI":"10.1055\/a-1089-7870"},{"key":"7","unstructured":"7  (2024) NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma (Version 5.2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf accessed on December 1, 2024."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, et al. (2015) Lenvatinib <i>versus<\/i> placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372: 621\u2013630.","DOI":"10.1056\/NEJMoa1406470"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, et al. (2015) Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 106: 1714\u20131721.","DOI":"10.1111\/cas.12826"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Takahashi S, Tahara M, Ito K, Tori M, Kiyota N, et al. (2020) Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan. Adv Ther 37: 3850\u20133862.","DOI":"10.1007\/s12325-020-01433-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Song E, Kim M, Kim EY, Kim BH, Shin DY, et al. (2020) Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea. Thyroid 30: 732\u2013738.","DOI":"10.1089\/thy.2019.0476"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Rendl G, Sipos B, Becherer A, Sorko S, Trummer C, et al. (2020) Real-world data for lenvatinib in radioiodine-refractory differentiated thyroid cancer (RELEVANT): a retrospective multicentric analysis of clinical practice in Austria. Int J Endocrinol 2020: 8834148.","DOI":"10.1155\/2020\/8834148"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Locati LD, Piovesan A, Durante C, Bregni M, Castagna MG, et al. (2019) Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer 118: 35\u201340.","DOI":"10.1016\/j.ejca.2019.05.031"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Wirth LJ, Durante C, Topliss DJ, Winquist E, Robenshtok E, et al. (2022) Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit. Oncologist 27: 565\u2013572.","DOI":"10.1093\/oncolo\/oyac065"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Capdevila J, Deandreis D, Durante C, Leboulleux S, Luster M, et al. (2023) Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice. Eur Thyroid J 12: e230068.","DOI":"10.1530\/ETJ-23-0068"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, et al. (2018) NCCN Guidelines insights: thyroid carcinoma, version 2.2018. J Natl Compr Canc Netw 16: 1429\u20131440.","DOI":"10.6004\/jnccn.2018.0089"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17 Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, et al. (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26: 1\u2013133.","DOI":"10.1089\/thy.2015.0020"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Taylor MH, Takahashi S, Capdevila J, Tahara M, Leboulleux S, et al. (2021) Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid 31: 1226\u20131234.","DOI":"10.1089\/thy.2020.0779"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Gianoukakis AG, Dutcus CE, Batty N, Guo M, Baig M (2018) Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer 25: 699\u2013704.","DOI":"10.1530\/ERC-18-0049"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Suzuki C, Kiyota N, Imamura Y, Goto H, Suto H, et al. (2019) Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer. Head Neck 41: 3023\u20133032.","DOI":"10.1002\/hed.25784"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Tahara M, Kiyota N, Hoff AO, Badiu C, Owonikoko TK, et al. (2021) Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 147: 51\u201357.","DOI":"10.1016\/j.ejca.2020.12.032"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48: 452\u2013458.","DOI":"10.1038\/bmt.2012.244"},{"key":"23","unstructured":"23 Murakami D, Nishimoto K, Takao S, Miyamaru S, Kadowaki T, et al. (2024) Significance of continuous low-dose lenvatinib for the treating of the patients with unresectable thyroid carcinoma. Acta Med Okayama 78: 63\u201370."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Matsuyama C, Enokida T, Ueda Y, Suzuki S, Fujisawa T, et al. (2023) Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front Oncol 13: 1139659.","DOI":"10.3389\/fonc.2023.1139659"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Fukuda N, Toda K, Wang X, Ohmoto A, Hayashi N, et al. (2021) Prognostic significance of 8 weeks\u2019 relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients. Endocr J 68: 639\u2013647.","DOI":"10.1507\/endocrj.EJ20-0754"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Yamazaki H, Sugino K, Matsuzu K, Masaki C, Akaishi J, et al. (2020) Rapid disease progression after discontinuation of lenvatinib in thyroid cancer. Medicine (Baltimore) 99: e19408.","DOI":"10.1097\/MD.0000000000019408"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Jiang HJ, Chang YH, Chen YH, Wu CW, Wang PW, et al. (2021) Low dose of lenvatinib treatment for patients of radioiodine-refractory differentiated thyroid carcinoma\u2014a real-world experience. Cancer Manag Res 13: 7139\u20137148.","DOI":"10.2147\/CMAR.S326255"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Capdevila J, Newbold K, Licitra L, Popovtzer A, Moreso F, et al. (2018) Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treat Rev 69: 164\u2013176.","DOI":"10.1016\/j.ctrv.2018.06.019"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, et al. (2022) Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. Expert Rev Anticancer Ther 22: 383\u2013400.","DOI":"10.1080\/14737140.2022.2039123"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Kim SY, Kim SM, Chang H, Kim BW, Lee YS, et al. (2019) Safety of tyrosine kinase inhibitors in patients with differentiated thyroid cancer: real-world use of lenvatinib and sorafenib in Korea. Front Endocrinol (Lausanne) 10: 384.","DOI":"10.3389\/fendo.2019.00384"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Brose MS, Panaseykin Y, Konda B, de la Fouchardiere C, Hughes BGM, et al. (2022) A randomized study of lenvatinib 18 mg <i>vs.<\/i> 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab 107: 776\u2013787.","DOI":"10.1210\/clinem\/dgab731"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, et al. (2019) Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 106: 61\u201368.","DOI":"10.1016\/j.ejca.2018.10.002"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, et al. (2009) Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 41: 67\u201372.","DOI":"10.4143\/crt.2009.41.2.67"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Ueda T, Uemura H, Tomita Y, Tsukamoto T, Kanayama H, et al. (2013) Efficacy and safety of axitinib <i>versus<\/i> sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol 43: 616\u2013628.","DOI":"10.1093\/jjco\/hyt054"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, et al. (2010) A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 40: 194\u2013202.","DOI":"10.1093\/jjco\/hyp146"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Shen CT, Qiu ZL, Luo QY (2014) Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Endocr Relat Cancer 21: 253\u2013261.","DOI":"10.1530\/ERC-13-0438"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Broome DT, Gadre GB, Fayazzadeh E, Bena JF, Nasr C (2020) Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma. Endocr Connect 9: 812\u2013823.","DOI":"10.1530\/EC-20-0193"},{"key":"38","unstructured":"38 Brownlie BJ, Turner J, Abdelaal AS (2012) Deaths due to differentiated thyroid cancer: a South Island, New Zealand experience: 1984\u20132009. N Z Med J 125: 13\u201321."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Ahmaddy F, Burgard C, Beyer L, Koehler VF, Bartenstein P, et al. (2021) (18)F-FDG-PET\/CT in patients with advanced, radioiodine refractory thyroid cancer treated with lenvatinib. Cancers (Basel) 13: 317.","DOI":"10.3390\/cancers13020317"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Marotta V, Rocco D, Crocco A, Deiana MG, Martinelli R, et al. (2024) Survival predictors of radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in real life. J Clin Endocrinol Metab 109: 2541\u20132552.","DOI":"10.1210\/clinem\/dgae181"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/12\/72_EJ25-0251\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:38:19Z","timestamp":1764992299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/12\/72_EJ25-0251\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0251","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ25-0251"}}